SUPERNEWS - NASDAQ:BIIB (Biogen Inc.) Stock Price, News, Quote, History

SUPERNEWS

매크로

주식

빅테크

오피니언

애널리스트 픽

급등락주

암호화폐

실적발표

Equities

Top Stories

유럽의약청, 알츠하이머 치료제 '레켐비' 승인 거부…바이오젠 주가 5%↓

13 hours ago

Intraday: 테슬라 11% 급등, 바이오젠·보스턴 실적호조

Biogen (BIIB) and Boston Scientific (BSX) shares surged 4.1% and 6.1%, respectively, on strong earnings, while Enphase Energy (ENPH) and Old Dominion (ODFL) fell by 4.7% and 10% due to disappointing forecasts. Tesla's (TSLA) stock leaped by 11%, defying expectations with its Q1 results, highlighting the market's dynamic nature with significant movements across various sectors.

4/24, 14:10 EDT

바이오텍 부활 조짐, 애널리스트 "5개 주목주 비중 확대"

Evercore ISI optimistic on biotech's rebound with a 49% drop since 2021, highlighting five stocks for potential growth.

5/14, 11:50 EDT

바이오기업 Ionis, Intellia, CSL 유전성 혈관부종 시장 주목

Citi highlights three biotech stocks in a growing $2.9 billion hereditary angioedema market, with CSL's treatment poised for 50% upside.

4/30, 19:35 EDT

Pre-Market: 임상 실패로 바이오주 급락, 오토데스크 상승

Aerovate Therapeutics (AVTE) and Ovid Therapeutics (OVID) saw massive declines of 91% and 68% respectively, due to failed clinical trials, highlighting biotech sector risks. Autodesk (ADSK) rose 4.7% on Starboard Value's $500M stake, while Xponential Fitness (XPOF) surged 25% following the appointment of former Taco Bell CEO Mark King.

6/17, 10:37 EDT

유럽의약청, 알츠하이머 치료제 '레켐비' 승인 거부…바이오젠 주가 5%↓

13 hours ago

Intraday: 테슬라 11% 급등, 바이오젠·보스턴 실적호조

4/24, 14:10 EDT

바이오텍 부활 조짐, 애널리스트 "5개 주목주 비중 확대"

5/14, 11:50 EDT

BIIB News

Intraday: 다우지수 1.8% 상승, 3M 21% 급등

9 hours ago

유럽의약청, 알츠하이머 치료제 '레켐비' 승인 거부…바이오젠 주가 5%↓

13 hours ago

Pre-Market: 미국 증시 선물 상승, 코세라 26% 급등

16 hours ago

다이어트 약 시장 1300억 달러…신규 진입자 주목

7/25, 19:33 EDT

릴리, 연 3만2000달러 알츠하이머 치료제 美 승인

7/2, 15:46 EDT

Pre-Market: 임상 실패로 바이오주 급락, 오토데스크 상승

6/17, 10:37 EDT

엘리 릴리 알츠하이머 신약 도나네맙, FDA 자문단 만장일치 승인 권고

6/10, 17:36 EDT

머크, 최대 30억달러 투자해 EyeBio 인수

5/29, 02:46 EDT

바이오텍 부활 조짐, 애널리스트 "5개 주목주 비중 확대"

5/14, 11:50 EDT

바이오기업 Ionis, Intellia, CSL 유전성 혈관부종 시장 주목

4/30, 19:35 EDT

Intraday: 테슬라 11% 급등, 바이오젠·보스턴 실적호조

4/24, 14:10 EDT

Intraday: 테크·금융주 급등에 증시 상승세, 실적부진株 하락

4/24, 10:45 EDT

실적 앞두고 Tesla·Rivian 목표가 하향 조정

4/18, 02:18 EDT

제약사들, 中바이오기업 겨냥 법안에 공급망 다변화

4/11, 00:07 EDT

바이오젠·맥도날드 저평가 주목, 상승 기대

4/5, 13:53 EDT

Aardvark·Viking, 비만치료제 시장 공략 본격화

3/29, 07:27 EDT

Nvidia Leads Wall Street Picks with 82% Surge

3/27, 19:50 EDT

FDA Delays Decision on Eli Lilly's Alzheimer Drug Amid Safety Concerns

3/8, 09:36 EST

Eli Lilly's Alzheimer's drug approval faces FDA delay, shares dip premarket

3/8, 07:43 EST

Florida Homeowners Brace for Insurance Premium Hikes Amid Climate Change Challenges

3/7, 15:48 EST

Nasdaq's Hidden Gems: Stocks with Over 20% Growth Potential

3/1, 14:38 EST

Wall Street Views

University College London

John Hardy, 7/26/24

Cautiously Optimistic on

BIIB

“The EMA decision will be revisited as US clinicians and others gather and report real-world experience.”

Cornell University

Costantino Iadecola, 6/10/24

Cautiously Optimistic on

BIIB

LLY

“If there are some subgroups where further analysis is required, this should not hold up making this drug available to the public.”

Mayo Foundation

Nilufer Ertekin-Taner, 6/10/24

Neutral on

BIIB

LLY

“More data was required for certain groups, including African Americans, Latin Americans and people with Down’s syndrome.”

Brian P. Skorney

Baird Analyst, 4/5/24

Bullish on

BIIB

MCD

“Optimism over Biogen’s potential expansion in Latin America, where the company can address roughly 2,000 to 4,000 patients for its spinal muscular atrophy treatment Spinraza.”